Anondita Medicare Limited H1 FY27 Profit Rises 69% to ₹22 Crore
Key highlights
- Anondita Medicare reported H1 FY27 consolidated net profit of ₹22.0 crore, up 69.2% year-on-year.
- Revenue from operations increased 35.9% year-on-year to ₹73.5 crore in H1 FY27.
- Operating margin improved to 39.8% from 31.9% in H1 FY26.
- Cash stood at ₹91.5 crore and work-in-progress for expansion was ₹74.2 crore at September 2026.
powered by IRIS

Anondita Medicare Limited reported consolidated net profit of ₹22.0 crore for H1 FY27, up 69.2% year-on-year, while revenue from operations increased 35.9% to ₹73.5 crore for the half year ended September 30, 2026. The results point to stronger profitability alongside revenue growth and a higher operating margin.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
What did Anondita Medicare report for H1 FY27?
Anondita Medicare reported consolidated revenue from operations of ₹73.5 crore and net profit of ₹22.0 crore in H1 FY27. Total income, including ₹0.6 crore of other income, stood at ₹74.1 crore. Profit before exceptional items and tax was ₹29.5 crore, which was also the reported profit before tax.
The company’s revenue increased from ₹54.1 crore in H1 FY26, while net profit rose from ₹13.0 crore. The result was disclosed through an NSE filing on November 14, 2026, after the board meeting held to consider and approve unaudited standalone and consolidated financial results for the half year ended September 30, 2026.
The source material contains a separate results summary that lists H1 FY27 net profit at ₹44 crore. However, the exchange update specifically reports consolidated profit after tax of ₹22.01 crore, and the detailed comparative results table reports net profit of ₹22.0 crore. This article uses the ₹22.0 crore figure supported by the detailed filing-based data.
How did margins and profits change from the previous year?
Anondita Medicare’s operating margin improved to 39.8% in H1 FY27 from 31.9% in H1 FY26. Operating profit, calculated before other income, grew 70.0% year-on-year, according to the results summary.
The improvement in margin accompanied a 35.9% rise in revenue and a 69.2% increase in net profit. Profit before tax increased to ₹29.5 crore from ₹17.4 crore a year earlier. These figures show that profit growth was faster than sales growth during the reported half year.
Compared with H2 FY26, revenue was lower than ₹83.3 crore, reflecting that the reported periods are different half years rather than directly comparable quarters. Net profit was higher than ₹21.3 crore in H2 FY26, while operating margin was also above the 35.2% reported in that period.
What is Anondita Medicare funding with recent capital raises?
Anondita Medicare said its cash balance rose to ₹91.5 crore following funds raised through its IPO, rights issue and warrants. The company reported work-in-progress of ₹74.2 crore for expansion and stated that the capital available was funding this ongoing investment.
The company also confirmed that there was no deviation in the use of IPO, rights issue and warrant proceeds, referring to the applicable monitoring agency reporting requirements. The disclosure is relevant because the business has recently raised capital while expanding its asset base and operations.
Board-related disclosures show that the company considered fund raising in April and August 2026, including a rights issue. The September 2026 balance sheet-related figures cited in the source show gross debt of ₹70.6 crore alongside the larger cash balance, although future cash use will depend on the pace of the disclosed expansion work.
Got a follow-up? Ask IRIS
How do the H1 figures compare with FY26 performance?
Anondita Medicare’s H1 FY27 revenue of ₹73.5 crore was more than half of its consolidated FY26 revenue of ₹137.4 crore, while H1 net profit of ₹22.0 crore was about two-thirds of FY26 profit of ₹34.3 crore. FY26 ended on March 31, 2026.
For FY26, the company’s annual report recorded consolidated revenue from operations of ₹137.4 crore and consolidated net profit of ₹34.3 crore. The company had reported consolidated total revenue of ₹138.3 crore for the year. Its standalone revenue from operations for FY26 was ₹111.7 crore, with standalone net profit of ₹26.8 crore.
The company’s prior reporting record also provides context for the latest disclosure. Its H1 FY26 results were filed on November 13, 2025, or 44 days after the September half-year end. The H1 FY27 results were filed on November 14, 2026, 45 days after the end of September 2026.
What does the result mean for investors and operations?
The H1 FY27 result matters because Anondita Medicare combined double-digit revenue growth with a wider operating margin and materially higher net profit. The ₹22.0 crore consolidated profit, supported by a 39.8% operating margin, is the central financial outcome in the filing.
For investors, the disclosed capital position and work-in-progress are important alongside the income statement. The company has stated that raised funds are being used without reported deviation and that ₹74.2 crore of work-in-progress relates to expansion. These disclosures provide context on how the company is allocating recently raised capital.
The results do not provide a formal revenue, profit or margin forecast for the rest of FY27. Therefore, the reported H1 improvement should be assessed as a half-year performance update rather than an indication of a confirmed full-year outcome. Investors will need to monitor subsequent financial filings, capital expenditure progress and working-capital trends.
Conclusion
Anondita Medicare delivered H1 FY27 consolidated revenue of ₹73.5 crore and net profit of ₹22.0 crore, representing year-on-year growth of 35.9% and 69.2%, respectively. The rise in operating margin to 39.8% indicates that profit expanded faster than revenue during the half year.
The next material disclosures will be updates on the company’s expansion work, the utilisation of funds raised through the IPO, rights issue and warrants, and its subsequent financial results. The company has confirmed no deviation in the use of these proceeds, while its work-in-progress stood at ₹74.2 crore in the reported period.


